Key Stats for Caris Life Sciences Stock
- Current Price: $24.58
- Target Price (Mid): ~$25
- Street Target: ~$27
- Street Target (High): ~$36
- Potential Total Return: ~2%
- Annualized IRR: ~0.5% / year
Now Live: Discover how much upside your favorite stocks could have using TIKR’s new Valuation Model (It’s free) >>>
What Happened?
Caris Life Sciences (CAI) closed at $24.58 on August 20, up 8% on the day and up 73% from the $14.19 low it hit on May 15. All summer, the debate was whether the selloff had gone too far. That debate is over. The stock has climbed back to roughly 42% below its $42.50 high. What replaced it is a harder call: after a record second quarter and a raised outlook, the stock has recovered most of the way back, yet it still trades below where analysts and the fundamentals point.
The rally has a clear cause. On August 5, Caris reported record revenue and raised full-year guidance, and the stock jumped 21.58% the next day. What has not been priced, and what the rest of this piece is about, is a margin lever management described on the call, but has not yet been put into the reported results.
A Record Quarter That Reset the Business, Not Just the Stock
The August 5 print was strong across the board. Revenue grew 45% year-over-year to $263.71 million, beating consensus by nearly 11%, driven by molecular profiling revenue up 55%. Management raised the full-year outlook to a range of $1.03 billion to $1.04 billion, and Caris posted its fifth straight quarter of positive adjusted EBITDA and free cash flow.
Caris completed roughly 59,200 clinical cases, up 18% year-over-year and 12% sequentially, its largest sequential case addition ever, as the blood-based Caris Assure test grew 50% year-over-year. That came after a first-quarter sales-force reorganization that briefly disrupted volume, so the reacceleration matters: it suggests the disruption is behind the company rather than lingering. Blended clinical average selling price crossed $3,850, a record.
Even after the rally, the stock does not look expensive against peers on revenue. Caris trades at 5.94x next-twelve-month revenue, below Natera at 14.74x and GRAIL at 13.59x, and modestly above Veracyte at 4.69x. The premium to Veracyte fits a company growing faster and running higher gross margins; the discount to the other two reflects their longer reimbursement track records in liquid biopsy. On revenue, the valuation multiple is priced for a solid grower, not a stretched one.
See historical and forward estimates for Caris Life Sciences stock (It’s free!) >>>
The Margin Lever the Market Is Not Pricing Yet
If there is fresh upside from this level, the most underappreciated source is cost, not just growth. GAAP gross margin already reached 68%, up from 63% a year ago, but management was explicit that it is not optimizing for margin yet. CFO Luke Power framed the philosophy directly: the company runs its assays “deeper, not cheaper,” choosing to add sequencing content rather than squeeze cost, “before we actually start squeezing.” That means today’s high-60s gross margin is a floor management has chosen, not a ceiling the business has hit.
President David Spetzler said two new sequencing suppliers have entered the market against the long-standing incumbent, with meaningfully higher throughput and lower cost, which “create the opportunity to increase our capacity and decrease our cost of goods simultaneously.” A blended clinical average selling price above $3,850, a record, is climbing at the same time. Rising price against falling unit cost is the combination that expands the gross margin a buyer at 86x earnings is implicitly counting on. It is real, and it is not yet in the reported numbers.
See how Caris Life Sciences performs against its peers in TIKR (It’s free!) >>>
TIKR Advanced Model Analysis
- Current Price: $24.58
- Target Price (Mid): ~$25
- Potential Total Return: ~2%
- Annualized IRR: ~0.5% / year
See analysts’ growth forecasts and price targets for Caris Life Sciences stock (It’s free!) >>>
The two revenue drivers carrying any upside are the same two that drove Q2: continued clinical case volume growth, guided to roughly 20% for the therapy-selection business, and further ASP gains as newer assays like ChromoSeq and Caris Assure add covered lives. The margin driver is the “deeper, not cheaper” cost lever, gross-margin durability in the high-60s with room to expand as new sequencing suppliers cut COGS. The primary risk is valuation itself: at 86x forward earnings, the model shows almost no cushion, so any slip in volume or ASP compresses the multiple fast.
The largest source of optionality outside the model is Caris Detect, the multi-cancer early detection test launched in June, which management excludes from guidance until it has a paid volume history. The upside case is that Detect converts its early demand, and that the September PAMA pricing update and pending New York State approval for blood testing, neither in the model, lift ASP and volume enough to carry the stock past the $27 mean toward the high target. The downside case is that the stock front-ran a still-early margin story and stalls near today’s price.
Conclusion
The catalyst to watch is Q3 2026 earnings, expected around early November based on prior cadence. Clinical case volume decides the first half of it: management guided to roughly 20% growth, landing near 61,000 to 62,000 cases, so a clear beat reads as the reorganization tailwind still building, and a miss reads as it fading. The second half is pricing. The September PAMA update and any New York State approval would show up in ASP and covered lives before they show up in guidance. The stock has already recovered most of its decline, so the next leg has to come from the fundamentals doing the work the rebound did this summer.
See what stocks billionaire investors are buying so you can follow the smart money with TIKR.
Should You Invest in Caris Life Sciences?
The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.
Pull up Caris Life Sciences, and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.
You can build a free watchlist to track Caris Life Sciences alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.
Analyze Caris Life Sciences on TIKR Free →
Looking for New Opportunities?
- See what stocks billionaire investors are buying so you can follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
